



Early detection of neovascular age-related macular degeneration: an economic 
evaluation based on data from the EDNA study 
 
Authors: 
Rodolfo Hernández1, Charlotte Kennedy1, Katie Banister2, Beatriz Goulao2, Jonathan Cook3, 
Sobha Sivaprasad4, Ruth Hogg5, Augusto Azuara-Blanco5, Heinrich Heimann6, Maria 




1. University of Aberdeen, Health Economics Research Unit, Aberdeen, UK. 
2. University of Aberdeen, Health Services Research Unit, Aberdeen, UK. 
3.  University of Oxford, Nuffield Department of Population Health, Oxford, UK. 
4.  NIHR Moorfields Biomedical Research Centre, London, Greater London, UK.  
5. Queen's University Belfast, Centre for Public Health Belfast, Belfast, UK  
6. Liverpool University Hospitals NHS Foundation Trust, St Paul’s Eye Unit, Liverpool, 
UK 
7. NHS Healthcare Improvement Scotland, Gyle Square, Edinburgh, UK. 
8. York Teaching Hospital NHS Foundation Trust, Ophthalmology, York, North 
Yorkshire, UK  
9. University of York, Department of Health Sciences, York, North Yorkshire, UK 
 
Correspondence to: Dr Graham Scotland, Health Economics Research Unit, University of 
Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK (Email: g.scotland@abdn.ac.uk)   
 
Word count: 3,498 
 
Contribution of authors: 
Rodolfo Hernández (Research Fellow, Health Economics) developed the model and 
conducted the economic analysis. Charlotte Kennedy conducted the costing survey and 
analyses of post-conversion visual acuity data to inform key model inputs. Katie Banister 
(Research Fellow, Trial Management) contributed to the conception and design of the study 
and was responsible for its day-to-day conduct and management. Beatriz Goulão (Research 




and diagnostic accuracy inputs for the economic model. Jonathan A Cook (Associate 
Professor, Statistics) contributed to the conception and design of the study and was 
responsible for the statistical analysis of time to conversion and diagnostic accuracy. Sobha 
Sivaprasad (Consultant, Ophthalmology), Ruth Hogg (Senior Lecturer, Vision Science) 
Augusto Azuara-Blanco (Consultant, Ophthalmology), and Heinrich Heimann (Consultant, 
Ophthalmology) all contributed to the conception and design of the study and provided 
clinical expertise and insights to inform key modelling assumptions. Maria Dimitrova 
contributed to the development of the economic model. Richard Gale (Consultant, 
Ophthalmology), Chief investigator of the parallel FASBAT study, provided clinical 
expertise and data to inform key model inputs and assumptions. Mia Porteous (Trial Manager 
for the FASBAT study) was responsible for the collection of post conversion visual acuity 
and treatment data for EDNA participants who subsequently converted and enrolled in the 
FASTBAT study (used to inform key modelling inputs). Craig Ramsay (Professor, Health 
Care Evaluation), Co-Chief Investigator of EDNA, contributed to the conception and design 
of the study and was methodological lead for the study. Usha Chakravarthy (Consultant, 
Ophthalmology), Chief Investigator of EDNA, led the conception and design of the study and 
the recruitment and follow-up of participants. Graham Scotland (Reader, Health Economics) 
contributed to the conception and design of the study, was responsible for the health 
economic objectives, and led the writing of this manuscript. All authors contributed to the 







This economic modelling study suggests that spectral-domain optical coherence tomography 
offers a cost-effective monitoring test for detecting the onset of neovascular age-related 






Background/Aims: To evaluate the cost-effectiveness of non-invasive monitoring tests to detect the 
onset of neovascular age-related macular degeneration (nAMD) in the unaffected second eye of 
patients receiving treatment for unilateral nAMD in a UK NHS hospital outpatient setting.  
 
Methods: A patient-level state transition model was constructed to simulate the onset, detection, and 
treatment of nAMD in the second eye.  Five index tests were compared: self-reported change in visual 
function, Amsler test, clinic measured change in visual acuity from baseline, fundus assessment by 
clinical examination or colour photography, and spectral domain optical coherence tomography (SD-
OCT). Diagnosis of nAMD was confirmed by fundus fluorescein angiography (FFA) before prompt 
initiation of anti-vascular endothelial growth factor treatment. Quality adjusted life years (QALYs) 
and costs of health and social care were modelled over a 25-year time horizon.  
 
Results: SD-OCT generated more QALYs (SD-OCT, 5.830; fundus assessment, 5.787; Amsler grid, 
5.736, patient’s subjective assessment, 5.630; and visual acuity, 5.600) and lower health and social 
care costs (SD-OCT, £19,406; fundus assessment, £19,649; Amsler grid, £19,751; patient’s subjective 
assessment, £20,198; and visual acuity, £20,444) per patient compared to other individual monitoring 
tests. Probabilistic sensitivity analysis indicated a high probability (97-99%) of SD-OCT being the 
preferred test across a range of cost-effectiveness thresholds (£13,000-£30,000) applied in the UK 
NHS.   
 
Conclusions: Early treatment of the second eye following FFA confirmation of SD-OCT positive 
findings is expected to maintain better visual acuity and health related quality of life and reduce costs 
of health and social care over the lifetime of patients.   
 







Neovascular age-related macular degeneration (nAMD) causes severe visual loss and is the 
most common cause of blindness in persons aged 50 years or over in the western world.1    
 
Visual acuity (VA) outcomes for people with nAMD have improved in recent years with the 
introduction of therapies targeting vascular endothelial growth factor (VEGF).2,3 However, 
there remains a substantial residual burden of visual morbidity.  The UK based IVAN trial, 
for example, which achieved longer-term follow-up of 99% of eligible patients following 
release from the trial protocol at two years, showed that eyes monitored and treated in routine 
practice (median follow-up of 3.3 years) lost distance visual acuity at a rate of 4.3 ETDRS 
letters per year.4 Furthermore, 20% had VA worse than 33 letters at the end of study eye 
monitoring.   
 
A high incidence of second eye involvement (8-10% per year),5 coupled with real world 
evidence showing that second eyes with good vision at treatment initiation maintain better 
VA over three years than first presenting eyes,6 provides strong rationale for closely 
monitoring the second eye of patients being treated for nAMD in one eye.   There is a clear 
need for an easily and rapidly performed cost-effective monitoring test that will detect the 
onset of nAMD in the second eye with high diagnostic accuracy.  
 
This paper reports on an economic evaluation conducted as part of the UK based EDNA 
study (Early Detection of Neovascular Age-related macular degeneration), which assessed 
the diagnostic monitoring performance of five candidate tests against a reference standard of 
fundus fluorescein angiography (FFA) over a 36-month follow-up period.7    
 
METHODS 
A patient-level state transition model was developed to simulate the long-term impact of 
candidate monitoring tests, carried out in UK NHS outpatient eye services, on visual acuity 
outcomes and health and social care costs over a 25 year time horizon. The model focused on 
the second eye of people commencing treatment for nAMD in one eye, and was structured 
around disease, diagnosis, and treatment status (Figure 1). Individuals were simulated to pass 
through the model one at time using a monthly cycle. Visual acuity (VA) was modelled as a 




to the point of conversion. It was also assumed that the second eye represented the best 
seeing eye (BSE) over the modelled time horizon. 
 
[Figure 1 here] 
 
Population 
The baseline characteristics of simulated individuals were drawn at random from a table 
containing the baseline characteristics of each EDNA study participant (n=552).  The average 
age was 77.4 years, mean baseline VA in the unaffected second eye was 79 letters compared 
to 56.6 in the first eye, and 57.2% were female. 
 
Comparators 
The model compared the monitoring tests under investigation in the EDNA study: SD-OCT 
(abnormal findings, indicative of nAMD), fundus evaluation (slit lamp biomicroscopy or 
fundus photography showing clinical signs of nAMD as determined by an expert), Amlser 
grid test (distortion or regions where the grid pattern disappears when previously no 
distortion present), patient subjective change in VA (much worse than the previous visit), and 
visual acuity (reduction of 10 or more letters in best corrected visual acuity from baseline). A 
secondary analysis also assessed the cost-effectiveness of the test combination with highest 
sensitivity (SD-OCT and fundus evaluation) and a test combination of all tests excluding 
OCT. The base case assumed that positive tests would be confirmed with FFA (the reference 
standard in the EDNA study) prior to treatment initiation.  
 
Time to conversion  
During the EDNA study, the second eye of 120 participants converted to nAMD as 
confirmed by local interpretation of FFA, and an additional 25 participants had a clinical 
determination of conversion without FFA, yielding a crude conversion rate of 26% (95% CI 
22.3%, 30.6%) with a median follow-up time of 33 months (ranging from 0.8 to 38.5 
months). Parametric survival analysis of time to conversion was conducted using local 
interpretation of FFA to define events. Individuals were censored at the time of their last 
observed FFA if no FFA-confirmed conversion was observed. An exponential curve was 
identified as having the best statistical fit to the observed data and was used in the model 






Time to losing ten or more ETDRS letters (without treatment) 
Following conversion of the second eye, time to deterioration of VA in the absence of 
treatment was informed by post-conversion visual acuity data on the 145 patients who 
converted during EDNA. VA data at time of treatment initiation and at one-year post-
conversion were obtained with permission from the parallel FASBAT study8 or routine case 
notes. Time of conversion was taken as the midpoint between the visit at which nAMD was 
detected and the preceding visit. Time at risk was calculated as the time from conversion to 
losing ten or more letters or treatment initiation (whichever came first). If no treatment was 
initiated, time at risk was censored at the last available follow-up point where VA data were 
available.   
 
The data were used to generate a Kaplan Maier curve, to which parametric survival functions 
were fitted (Supplementary Figure 2). Given uncertainty around the exact timing of events 
and the shape of the distribution, we selected the exponential curve for the base case 
extrapolation.  
 
We then used the difference in VA between the first presenting eye and the second eye 
(EDNA study eye) at baseline as a proxy to estimate the proportion of first presenting eyes 
that had lost 10 or more letters and 30 or more letters between conversion and treatment 
initiation; 78.4% and 29.2% respectively. It was assumed that untreated, 29.2% of second 
eyes can be expected to have lost 30 or more letters by the time 78.4% have lost 10 or more 
letters (15.15 months based on extrapolation). We used the relative difference to approximate 
a curve for time to losing 30 or more letters (supplementary Figure 2).  Exact numbers of 
letters lost were drawn randomly from a uniform distribution (minimum 10, maximum 29) 
for those modelled to lose 10-29 letters, and from a gamma distribution (mean = 42, standard 
deviation = 9.27, minimum = 30) for those losing 30 letters or more prior to treatment 
initiation; again, informed by the difference between the first presenting eye and the EDNA 
study eye at baseline. 
 
Diagnostic accuracy 
Test sensitivity and specificity were derived from the EDNA analysis of index test results at 




to account for lack of independence between repeated test observations within individuals 
(Table 1).  
 
Since the cost-effectiveness modelling was based on expected changes in VA following 
conversion to nAMD, and VA loss ≥ 10 letters was one of the index tests, we assumed VA 
change to have zero sensitivity for nAMD prior to any VA loss, and 100% sensitivity 
following VA loss ≥ 10 letters.  
 
Table 1 Diagnostic accuracy estimates applied in the economic model    


















Amsler 26.5 (18.8, 36.1) 93.7 (90.1, 96.1) 0.1398 13.8 0.9891 
Fundus 49.6 (40.8, 58.4) 
99.7 (98.2, 
100.0) 
0.02 14.2 0.9986 
OCT 90.0 (83.2, 94.3) 96.4 (93.8, 98.0) 0.0965 14.5 0.9930 
Self-reported 
vision 




88.4 (84.5, 91.4) 0.182 15.5 0.9871 
OCT or Fundus 92.4 (86.1, 96.1) 96.1 (93.4, 97.8) 0.140+ 17.6+ 0.9915+ 
All tests 
excluding OCT 
63.9 (54.0, 72.8) 85.9 (81.2, 89.6) 0.444+ 17.6+ 0.9673+ 
a Proportion of patients coded as false positive for each test at any testing visit throughout the EDNA study; b 
Adjusted specificity calculated as = (1-a)^(1/mean number of tests), so that its application over the observed 
mean number of tests in EDNA yielded the observed cumulative proportion experiencing a false positive on 
each test; +Adjusted specificities for combinations were calculated using the cumulative proportion of non-
convertors experiencing a false positive over follow-up, and the expected number of tests over 36 months of 
monitoring;  c represents overall sensitivity of the VA test for detecting observed EDNA cases, which is 
combination of 100% sensitivity for detecting cases that had lost ten or more letters from baseline, and 0% 





Post-treatment visual acuity trajectories 
For eyes that had lost 10 or more letters prior to treatment initiation, an average improvement 
in VA of +6.47 (95% CI: 2.66 - 10.28) was applied over the loading phase (EDNA post-
conversion data). For those commencing treatment prior to losing 10 or more letters, the 
average change in VA over the loading phase was assumed zero (Supplementary Table 1). 
External literature shows that second eyes with good VA at treatment initiation, on average 
do not accrue any significant improvement in VA over the loading phase, but maintain better 
VA at two to three years compared to eyes with poorer VA at treatment initiation.6,9 Post-
loading phase changes in VA were informed primarily by data from the ranibizumab arm of 
the UK based IVAN trial.10,11 Following the approach described by Claxton et al.,12  we 
applied random draws from time dependent normal distributions for VA change per month 
(Supplementary Table 1).  Beyond 24 months, we specified a monthly VA change 
distribution based on the annual rate of decline in distance VA observed during the long-term 
follow-up of IVAN participants; 4.3 letters per year (95% confidence interval: 3.7 to 4.9). 
Mean VA trajectories for eyes treated before and after significant vision loss (≥10 letters) are 
provided in Supplementary Figure 3. 
 
Treatment discontinuation 
Monthly probabilities of treatment discontinuation were applied from 24 months following 
treatment initiation (Supplementary Table 2).4 We further assumed that treatment and 
monitoring would cease for futility if vision dropped below 18 letters.  For those who 
discontinued treatment with VA better than 18 letters, stability was assumed and no further 
changes in VA were modelled unless reactivation and re-initiation of treatment ocurred.  
Since data on the rate of treatment re-initiation were not available from IVAN, we informed 
this using data provided by the authors of another UK based cohort study (Personal 
communication, Sobha Sivaprasad, March 2020)13  (Supplementary Table 2). 
 
Valuation of visual acuity outcomes 
Health state utility data by VA status was identified from searches of the published 
literature.14-22,23 For consistency with the NICE appraisals of ranibizumab and aflibercept,24,25 
we applied utilities reported by Czoski-Murray et al.22 based on UK general population time 
trade-off values for visual impairment states simulated using contact lenses. In line with the 
NICE appraisals, we used the published equation based on regression analysis of this data to 





Resource use and costs 
The model included costs of testing and monitoring for conversion to nAMD, monitoring and 
treatment post conversion, and health and personal social care associated with severe visual 
loss.  All costs were expressed in 2018/2019 UK Sterling, inflated when required using the 
NHS cost inflation index.26   
 
For each test, we assessed the time required to perform it and the time required to interpret it, 
for both eyes and for one eye. The times required and the grades of staff performing each role 
were based on a survey of centres participating in EDNA (18 of 24 responding), and these 
were combined with published unit cost multipliers for hospital staff (inclusive of 
overheads).26  Prices of test specific equipment, obtained from centres or manufacturers, were 
annuitized over their expected useful life span, and allocated on a per test basis using reported 
throughput.  Equipment costs per patient were further allocated between the first and second 
eye based on the estimated time required to test the first and second eye.    
 
Since monitoring of the second eye (EDNA study eye) coincided with monitoring of the 
treated (first presenting) eye, the marginal cost of assessing the second eye with each test was 
estimated and applied on top of the cost of a standard outpatient monitoring visit 
(Supplementary Table 4).27 The frequency of testing was based on observed average time 
interval between tests in EDNA, which increased over the 36 month follow-up. This equated 
to seven tests in year one, six in year two, and five in year three. In subsequent years we 
carried forward the frequency observed in the final 6 months of EDNA (four per patient year) 
out to five years. Beyond five years, it was assumed that monitoring for conversion of the 
second eye would continue at a reduced frequency of twice per year, and the cost of testing 
one eye was applied from this point onwards (assuming the majority of first treated eyes 
would be discharged from treatment by this time).  We also assessed a scenario which 
assumed no further monitoring for conversion from five years. 
 
Following conversion of the second eye, treatment and monitoring costs were applied 





Where vision dropped below 35 letters, health and social care costs associated with legal 
blindness were applied.28 Unit costs of post-conversion monitoring and treatment are 
provided in supplementary Table 6.27,29,30  
 
Analysis methods 
Monte Carlo simulation was used to propagate the passage of 200,000 individuals through the 
model.  Future costs and QALYs were discounted a rate of 3.5% beyond year one.31    
 
Incremental cost-effectiveness ratios, expressing the additional cost per QALY gained, were 
estimated by comparing each testing strategy to the next less costly strategy (excluding those 
found to be more costly and less effective than an alternative option).  
 
Probabilistic sensitivity analysis was performed by assigning probability distributions to each 
input parameter based on reported means and measures of variance in the accompanying 
Tables. Beta distributions were assigned to sensitivity and specificity parameters, gamma 
distributions were used for costs of testing and blindness (assuming a standard error of 10% 
of the mean), and normal distributions were applied to all other parameters. The PSA used 
5000 first order simulations for each of 1,000 random draws from the assigned second order 
probability distributions. The output from this analysis provides the probability of each 
monitoring test being preferred by increasing cost-effectiveness thresholds.32 Further 
deterministic scenario analysis was undertaken to assess the impact on findings of uncertainty 






The results of the base case analysis indicate that more sensitive monitoring tests generate 
increased health benefits at a lower cost, with SD-OCT being most effective and least costly 
and VA change being least effective and most costly, and (Table 2).   
 






OCT 19,406  5.830   
Fundus clinical 
evaluation 19,649 243 5.787 -0.044 -5,562** 
Amsler  19,751 346 5.736 -0.095 -3,656** 
Self-reported vision 20,198 792 5.630 -0.200 -3,961** 
Visual acuity 20,444 1,039 5.600 -0.230 -4,510** 
**Absolutely dominated 
 
The index tests with lower sensitivity and specificity accrue higher pre-diagnosis costs than 
more sensitive / specific strategies due to more visits prior to detection and increased chances 
of a false positive result (Supplementary Table 8). More sensitive index tests accumulate 
higher post-diagnosis monitoring and treatment costs resulting from earlier detection.  The 
increased costs of earlier treatment, however, are more than offset by reduced costs 
associated with visual impairment and blindness.  
 
The modelling suggests that compared to using VA alone, SD-OCT monitoring brings 
detection forward by approximately 7.5 months, for a mean gain in VA at time of treatment 
initiation of approximately 16 letters (Table 3).  It is this earlier initiation of treatment and 







Table 3 Model output: time lags from conversion to detection and 1st treatment and 





Time difference (months) 
Visual Acuity at 
1st treatment 
Conversion to 
nAMD to detection 
Conversion to nAMD 
to 1st treatment 
Detection to 
1st Treatment 
mean (sd) mean (sd) mean (sd) mean (sd) 
OCT 2.5 (1.8) 3.3 (1.8) 0.8 (0.4) 71.3 (13.4) 
Fundus clinical 
evaluation 4.1 (3.7) 4.8 (3.7) 0.7 (0.5) 68 (14.6) 
Amsler  5.9 (5.4) 6.4 (5.4) 0.5 (0.5) 64.4 (15.1) 
Self-reported 
vision 9.4 (8.4) 9.5 (8.4) 0.1 (0.3) 57.2 (13.3) 
Visual acuity 10 (9.2) 10.2 (9.2) 0.2 (0.4) 55.2 (11.8) 
 
 
Results of the probabilistic sensitivity analysis show consistency with the base case 
deterministic results (Supplementary Table 9).  The cost-effectiveness acceptability curves 
(Figure 2) indicate that SD-OCT has a very high chance of being the preferred strategy across 
a range of cost-effectiveness thresholds typically applied by NHS decision making bodies. 
 
[Figure 2 here] 
 
The results of the scenario analyses detailed in supplementary Table 7 are reported in 
supplementary Table 10. They indicate that the ICER for SD-OCT remains below £20,000 
per QALY for all the scenarios tested.   
 
In a scenario in which treatment is withheld until vision drops below 70 letters, the QALY 
gain associated with SD-OCT is diminished and its ICER increases to £19,488 
(Supplementary Table 10, scenario 15). However, it can be noted that this delayed treatment 
strategy results in greater costs and lower QALYs compared to the base case which assumes 
immediate initiation of treatment.   Similarly, the base case strategy of confirming SD-OCT 
positive results with an FFA prior to treatment initiation is less costly and of equal efficacy to 
the alternative strategy of treating all OCT positive cases without a confirmatory FFA 





In a secondary analysis, we assessed cost-effectiveness when including two combination 
strategies: 1) positive findings on SD-OCT or fundus examination counting as a positive 
result; and 2) positive findings on any test apart from OCT counting as a positive result 
(Table 4).  The combined SD-OCT/fundus strategy generates a very small QALY gain over 
SD-OCT alone. However, the increased testing cost results in the ICER being above accepted 
cost-effectiveness thresholds. The combination of all other tests, excluding OCT, generates 
higher costs and lower QALYs compared to OCT on its own and in combination with fundus 
evaluation (Table 4). 
 







OCT £19,406  5.830   
Fundus evaluation £19,649 £243 5.787 -0.044 -£5,560** 
Test combination 
(OCT+Fundus) 
£19,729 £323 5.833 0.002 £137,711 
Amsler grid £19,752 £23 5.736 -0.097 -£233** 
Patient's subjective assessment £20,199 £470 5.630 -0.202 -£2,320** 
Test combination (no OCT) £20,203 £473 5.806 -0.027 -£17,557** 







The results of this study suggest that of the individual tests that were assessed, SD-OCT can 
be expected to generate the most quality adjusted life years and lowest health and social care 
costs when used to monitor the second eye of patients with unilateral nAMD.  The increased 
costs associated with earlier detection and treatment are offset by a reduction in the costs 
which are associated with severe visual impairment. The QALY gains for SD-OCT are driven 
by the maintenance of better visual acuity in the second eye due to earlier detection, allowing 
earlier treatment initiation.  
 
By adopting an individual simulation approach, we were able to model VA as a continuous 
variable, which ensured the model outputs were sensitive to changes in VA.  Key inputs 
including time to conversion and diagnostic accuracy were informed by the prospective 
EDNA study.  In addition, resource use associated with pre-conversion monitoring was based 
on a survey of centres participating in the EDNA study, and post-detection treatment costs 
were based on pragmatic NHS based trials, supporting the generalisability of the model 
findings to the NHS.  Finally, post-treatment VA changes were also carefully informed by a 
range of sources applicable to NHS routine practice and capture expected differences in VA 
trajectories by degree of visual loss in the second eye prior to treatment initiation.  
 
Limited data were available to inform the rate of VA loss in untreated eyes immediately 
following conversion to nAMD.  Whilst the EDNA study was able to provide a reasonable 
estimate of the proportion expected to lose 10 or more letters within 3-6 months of 
conversion, the tendency to treat prior to significant vision loss resulted in uncertainty around 
the extrapolation of this input.  However, more conservative extrapolations were explored, 
and the ICER for SD-OCT remained favourable.  To ensure the impact of visual loss in the 
EDNA study eye (second eye) was not underestimated, the second eye was assumed to 
represent the better seeing eye over the model time horizon.  Whilst this will hold true for the 
majority, VA in the second eye may drop below that of the first eye in some patients.  Thus, 
the model may slightly overestimate the health benefits and cost savings of early detection 
and treatment.  In line with the EDNA study design, the analysis was conducted for a cohort 
of patients being monitored in UK NHS hospital eye services. Therefore, the cost-
effectiveness findings do not generalise directly to contexts where monitoring of the second 
eye occurs in the community. If the superior diagnostic performance of OCT observed in 




option in this context. However, this would also depend on the comparative costs of the 
different diagnostic tests when carried out in the community, and a detailed assessment of 
this was outside the scope of EDNA.  Similarly, generalisability outside the UK NHS is 
uncertain.   
 
To our knowledge this is the first study to assess cost-effectiveness of alternative diagnostic 
monitoring strategies for nAMD in the second eye of patients being treated for unilateral 
nAMD.  In a previous health technology assessment, Mowatt et al. reported a high degree of 
uncertainty regarding the optimal use of SD-OCT in the nAMD monitoring and treatment 
pathway.28 This was in part due to limitations in the evidence base for diagnostic accuracy 
available at the time.  The EDNA study has provided robust evidence for the high diagnostic 
accuracy of SD-OCT as a monitoring test for the early detection of nAMD in the second eye, 
and the economic modelling reported here suggests it is likely to offer a cost-effective 
strategy in this context.  
  
We are aware of one study that has assessed the cost-effectiveness of immediate anti-VEGF 
treatment in patients with VA better than 70 letters at detection compared to waiting for VA 
to drop below 70 letters.33  Using data from the nAMD UK database on patients with VA 
above 70 letters at detection, Butt and colleagues estimated the time for VA to a drop below 
70 letters without treatment. Their modelling suggested that immediate treatment would 
maintain better VA and offer a cost-effective use of NHS resources in the short to medium 
term (2-10 years).  Our modelling produced consistent findings but using a lifetime horizon, 
and including costs associated with severe visual impairment, we found immediate treatment 
based on FFA confirmed SD-OCT positive findings to offer a potentially cost-saving 
approach.   
 
The modelling reported here suggests that SD-OCT, compared to other available diagnostic 
monitoring tests, can lead to substantial reductions in the time to diagnosis and treatment of 
nAMD in the second eye of patients being monitored and treated for nAMD in their first eye.  
The early initiation of treatment in the second eye, based on FFA confirmed SD-OCT 
positive findings, can be expected to maintain better VA and health related quality of life 
compared to less sensitive monitoring strategies, and may deliver cost-savings in the long-





Our base case analysis reflected NICE diagnostic guidance to use FFA to confirm the 
diagnosis of nAMD.34  Clinical practice might vary towards initiating treatment based on SD-
OCT results alone.  While our modelling suggests it is more cost-effective to first confirm the 
diagnosis of nAMD using FFA rather than proceeding straight to treatment in all OCT 
positive cases, it is possible that clinical judgment may be applied in practice to efficiently 
circumvent the need for FFA in some cases without risking inappropriate overtreatment of 
false positive patients. Finally, considering the value of using fundus evaluation alongside 
OCT, our modelling suggests that the additional cost may not be justified given the marginal 
gain in sensitivity.  
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by time since treatment initiation (EDNA model) 
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Supplementary Table 9 Probabilistic cost-effectiveness results 
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Supplementary Table 1 VA change for treated individuals from treatment initiation to 
24 months 
Variable Point estimate 
(SD) 
Source 
Monthly VA change (months 1-
3) for eyes with VA loss ≥ 10 
letters 
2.1567 (2.89) Chakravarthy et al., 
Claxton et al., 10,12 
EDNA post-conversion data 
Monthly VA change (months 3 
– 12) for eyes with VA loss ≥ 10 
letters. 
0.00 (2.25) Chakravarthy et al., 
Claxton et al., 10,12 
 
Monthly VA change 
(months 13-24) for eyes with 
VA loss ≥ 10 letters 
-0.0917 (2.17) Chakravarthy et al., 




Supplementary Table 2 Probabilities of treatment discontinuation and treatment re-
initiation 
Variable Estimated 
probability (SE)a  
Source 
Monthly probability of treatment 
discontinuation by VA at 24 months 
post-treatment initiation  
 Evans et al. 20204 
≥ 68 0.0091 (0.001)  
53-67 0.0143 (0.002)  
38-52 b 0.0095 (0.003)  
≤ 37 0.0257 (0.007)  
Overall 0.0174 (0.001)  
Average of 38 to ≥ 68  0.0110 (0.002)  
Annual probability of re-initiating 
treatment following 12 months stable  
 Chandra et al. 2020;13  
Personal communication, 
Sohba Sivaprasad, March 
2020. 
Year 1 0.246 (0.038)  
Year 2 onwards 0.106 (0.038)  
a Point estimates and standard errors calculated by the authors from the reported data  
 
  
Supplementary Table 3 Health state utility inputs  
Utility parameters Mean Standard error 
Constant (baseline) 0.86 0.068 
Decrement per unit 
increase in VA 
LogMAR 
-0.368 0.046 
Decrement per one 
year increase in age 
-0.001 0.002 
Source, Czoski-Murray et al.22   
Supplementary Table 4 Testing costs applied in the model 
 Index test modality 
OCT  
(£) 











Mean 10.68 10.64 11.79 6.13 7.08 8.15 
St. dev 5.19 6.32 7.11 3.05 6.68 6.32 
Median 9.71 9.91 10.04 4.83 5.05 6.26 





Mean 19.45 18.44 13.70 6.88 8.07 10.23 
St. dev 10.14 8.85 7.33 2.92 7.35 6.50 
Median 17.83 20.24 12.11 7.10 5.33 7.34 
IQR 11.76 13.23 9.72 3.40 4.80 6.21 
Total Mean 30.13 30.79 25.48 13.01 15.14 18.38 
St. dev 14.50 10.72 13.18 5.85 13.73 12.16 
Median 29.12 31.58 22.15 12.89 10.82 13.68 
IQR 16.47 11.58 16.97 6.14 8.82 5.36 
  
Supplementary Table 5 Monitoring and treatment frequency after conversion to nAMD 
 Ranibizumab Aflibercept 
 Treatment visits 











Year 1 10 (0.233) 12c 7 (0.35) 7 (0.35) 
Year 2 8 (0.233) 12c 6 (0.3) 6 (0.3) 
Year 3+ 4 (0.277) 9 (0.231) 4 (0.2) 6 (0.3) 
Notes: SE, standard error; a, standard errors approximated from reported medians and inter-quartile 
ranges; b, standard errors assumed as 5% of the mean; c, applied deterministically.  The base case 
analysis assumed a drug treatment distribution in line with the observed distribution in patients who 
commenced treatment in their EDNA study eye; aflibercept (68.7%), ranibizumab (22.3%), and 
bevacizumab (9%). 
  
Supplementary Table 6 Unit costs for monitoring and treatment following conversion to 
nAMD 
Resource Unit costs Source  Notes 
Ophthalmology 
outpatient visit 
£95 National Cost 
Collection 
2018-1927 
Code 130 Outpatient consultant led 
appointment in ophthalmology  
Fluorescein angiography 
(FFA) 
£145 National Cost 
Collection 
2018-1927 
BZ86B Outpatient intermediate 
vitreous retinal procedures 
Administration of anti-
VEGF injection  
£145 National Cost 
Collection 
2018-1927 
BZ86B Outpatient intermediate 
vitreous retinal procedures 
Ranibizumab (Lucentis) 
injection 
£551 BNF, 201929  1.65mg/0.165ml solution for 
injection pre-filled syringes 
(Novartis Pharmaceuticals UK Ltd) 
Aflibercept (Eylea 
injection) 
£816 BNF, 201929 2mg/50microlitres solution for 
injection vials (Bayer Plc) 
Bevacizumab (Avastin 
injection) 
£49 Dakin et al., 
201430 
1.25 mg per injection  




month in year 1 
£541.73 per 








Supplementary Table 7 Details of scenario analyses carried out 
Scenario Description 
1. The Weibull distribution applied to model time to conversion to nAMD, giving an 
increasing hazard of conversion over time.  
2. The lognormal distribution applied to model time to conversion to nAMD, giving a 
decreasing hazard of conversion over time. 
3. The Lognormal distribution applied to model time from conversion to nAMD to 
significant vision loss (≥10 letters) 
4. The generalised gamma distribution applied to model time from conversion to 
nAMD to significant vision loss (≥10 letters) 
5. Pre-treatment VA loss conditional on dropping 10-29 and ≥30 letters assumed to be 
skewed towards the lower end of the VA loss ranges; mean = 12 and mean 32 letters, 
respectively   
6. A reduced longer-term rate of post-treatment VA decline applied; 3.1 letters per year 
in line with the average rate of decline estimated for younger patients (aged 70) in 
the IVAN long-term follow-up study. 
7. A reduced longer-term rate of post-treatment VA decline applied; 2 letters per year 
in line with the average rate of decline estimated for younger patients (aged 60) in 
the IVAN long-term follow-up study 
8. Distribution for long-term post-treatment rate of VA loss per year assumed to be 
right skewed and constrained by 0; gamma distribution with mean=4.3, standard 
deviation = 7.   
9. A reduced rate of treatment discontinuation for stable vision applied (0.0092), based 
on data from Chandra et al. (applied independent of VA outcome at 24 months post 
treatment) 
10. Removal of treatment discontinuation for stable vision (an extreme scenario to assess 
the impact of this uncertain parameter). 
11. An increased rate of treatment re-initiation (approximately 2.9% per month) 
following discontinuation for stable disease, in line with data reported by 
Madhusudhana et al (2016).83  
12. 100% test sensitivity applied for all tests at the subsequent monitoring visit for those 
who lose 15-29 letters due to nAMD. 
13. Removal of excess mortality associated with visual impairment. 
14. Removal of costs of blindness 
15. Wait to treat policy, which assumes VA must drop below the threshold specified for 
ranibizumab and aflibercept in NICE TA guidance (≤70  letters).  
16. Treatment instigated following OCT positive findings, without confirmation with 
FFA – this assumes that any patient receiving a false positive OCT result incurs 12 
months’ worth of anti-VEGF treatment inappropriately, before being identified as 
morphologically unchanged and treatment withdrawn.  
17. Increased test monitoring costs as per the increased overhead scenario outlined in the 
health economics appendix.  
18. Assume no further monitoring for conversion from 5 years, based on the probability 
that a majority of first eyes may be discharged from active treatment by this time 
point.   
   
Supplementary Table 8 Break down of costs for the base case analysis 






diagnosis Treatment Blindness 
OCT 19,406 2,573 2,576 10,966 3,291 
Fundus clinical 
evaluation 19,649 2,588 2,506 10,685 3,870 
Amsler  19,751 2,502 2,426 10,362 4,461 
Self-reported vision 20,198 2,565 2,261 9,700 5,672 
Visual acuity 20,444 2,644 2,226 9,562 6,013 
 
 





Cost (£) QALYs 
Incremental 
QALYs ICER (£) 





evaluation 19,900  240 5.796 -0.046 Dominated 
Amsler  20,069  169 5.744 -0.098 Dominated 
Self-reported vision 20,659  590 5.644 -0.198 Dominated 
Visual acuity 20,900  242 5.615 -0.227 Dominated 
 
  
Supplementary Table 10 Results of cost-effectiveness scenario analyses 
Strategy Cost (£) 
Incremental 
Costs (£) QALYs 
Incremental 
QALYs ICER (£) 
1. Weibull distribution applied to model time to conversion to nAMD, giving an increasing hazard 
of conversion over time 
OCT 19,909  5.806   
Fundus clinical evaluation 20,178 269 5.761 -0.046 -5,898** 
Amsler  20,290 381 5.709 -0.098 -3,892** 
Self-reported vision 20,754 845 5.601 -0.205 -4,123** 
Visual acuity 20,993 1,084 5.572 -0.235 -4,617** 
2. LogNormal distribution applied to model time to conversion to nAMD, giving a decreasing 
hazard of conversion over time 
OCT 17,288  5.926   
Fundus clinical evaluation 17,501 212 5.888 -0.037 -5,687** 
Amsler  17,550 261 5.843 -0.083 -3,163** 
Self-reported vision 17,969 681 5.748 -0.178 -3,826** 
Visual acuity 18,219 931 5.721 -0.205 -4,545** 
3. Lognormal distribution applied to model time from conversion to nAMD to losing 10 or more 
letters without treatment.  
OCT 19,616  5.806   
Fundus clinical evaluation 19,854 238 5.765 -0.041 -5,773** 
Amsler  19,899 283 5.723 -0.083 -3,406** 
Self-reported vision 20,049 433 5.644 -0.161 -2,679** 
Visual acuity 20,112 496 5.620 -0.186 -2,672** 
4. Generalised gamma distribution applied to model time from conversion to nAMD to losing 10 or 
more letters without treatment.  
Visual acuity 18,853  5.688   
Self-reported vision 19,311 458 5.690 0.002 293,816* 
OCT 19,760 907 5.788 0.100 9,040 
Amsler  19,833 73 5.728 -0.060 -1,229** 
Fundus clinical evaluation 19,912 153 5.756 -0.032 -4,745** 
5. Letter losses conditional on dropping 10-29 and ≥30 letters assumed to be skewed towards the 
highest end of the range; mean = 12 and mean 32 respectively   
Self-reported vision 18,728  5.780   
Amsler  18,755 27 5.836 0.057 470 
Visual acuity 18,831 76 5.763 -0.073 -1,037** 
Fundus clinical evaluation 18,867 112 5.861 0.025 4,478* 
OCT 18,878 123 5.883 0.046 2,655 
6. Reduced long-term rate of post treatment VA decline from 4.3 letters per year to 3.1 letters per 
year 
OCT 18,592  5.925   
Fundus clinical evaluation 18,839 247 5.878 -0.047 -5,237** 
Amsler  18,975 382 5.822 -0.102 -3,733** 
Self-reported vision 19,455 863 5.703 -0.221 -3,897** 
Visual acuity 19,690 1,097 5.671 -0.253 -4,331** 
7. Reduced long-term rate of post treatment VA decline from 4.3 letters per year to 2 letters per year 
OCT 17,987  6.016   
Fundus clinical evaluation 18,193 206 5.965 -0.051 -4,067** 
Amsler  18,289 302 5.906 -0.110 -2,748** 
Self-reported vision 18,712 725 5.778 -0.238 -3,045** 
Visual acuity 18,915 929 5.744 -0.272 -3,415** 
8. Distribution for long-term post-treatment rate of letter loss per year assumed to right skewed and 
constrained by 0; gamma distribution with mean=4.3, standard deviation = 7 
OCT 19,132  5.954   
Amsler  19,182 51 5.839 -0.115 -441** 
Fundus clinical evaluation 19,184 52 5.899 -0.055 -944** 
Self-reported vision 19,464 333 5.729 -0.226 -1,475** 
Visual acuity 19,614 482 5.696 -0.258 -1,870** 
9. Reduced rate of treatment discontinuation for stable vision to 0.0092 based on data from Chandra 
et al. 
OCT 19,957  5.816   
Fundus clinical evaluation 20,175 218 5.772 -0.043 -5,028** 
Amsler  20,265 307 5.722 -0.094 -3,284** 
Self-reported vision 20,699 741 5.619 -0.197 -3,765** 
Visual acuity 20,934 976 5.588 -0.227 -4,292** 
10. No treatment discontinuation for stable vision  
OCT 23,854  5.723   
Amsler  23,857 3 5.640 -0.082 -36** 
Fundus clinical evaluation 23,941 87 5.686 -0.037 -2,373** 
Self-reported vision 23,978 124 5.549 -0.173 -715** 
Visual acuity 24,124 269 5.524 -0.199 -1,356** 
11. Increased rate of re-initiation of therapy following discontinuation with stable vision.   
OCT 20,457  5.792   
Fundus clinical evaluation 20,664 207 5.751 -0.042 -4,973** 
Amsler  20,725 268 5.703 -0.090 -2,989** 
Self-reported vision 21,104 647 5.602 -0.191 -3,390** 
Visual acuity 21,329 872 5.574 -0.219 -3,990** 
12. 100% test sensitivity applied for all tests at the next monitoring visit for those who lose 15-30 
letters due to nAMD 
OCT 19,405  5.830   
Fundus clinical evaluation 19,640 236 5.786 -0.044 -5,359** 
Amsler  19,740 336 5.736 -0.095 -3,545** 
Self-reported vision 20,189 784 5.630 -0.200 -3,913** 
Visual acuity 20,442 1,037 5.600 -0.231 -4,497** 
13. No excess mortality due to VA loss 
OCT 20,234  5.931   
Fundus clinical evaluation 20,531 297 5.887 -0.044 -6,716** 
Amsler  20,692 458 5.837 -0.094 -4,876** 
Self-reported vision 21,259 1,025 5.734 -0.197 -5,195** 
Visual acuity 21,542 1,308 5.705 -0.227 -5,774** 
14. Removal of costs of blindness 
Visual acuity 14,432  5.600   
Self-reported vision 14,527 95 5.630 0.030 3,144 
Amsler  15,290 763 5.736 0.106 7,231 
Fundus clinical evaluation 15,779 489 5.787 0.051 9,621* 
OCT 16,115  825 5.830 0.095 8,729  
15. Wait for VA to drop to 70 letters or lower before initiating treatment, regardless of VA at time 
of detection  
Self-reported vision 20,423  5.580   
Amsler  20,471 48 5.591 0.012 4,159 
Visual acuity 20,484 14 5.578 -0.014 -1,001** 
Fundus clinical evaluation 20,630 159 5.597 0.005 31,014* 
OCT 20,651 181 5.601 0.009 19,488 
16. Initiating anti-VEGF treatment on the back of OCT positive findings, without confirmation with 
FFA 
Fundus clinical evaluation 19,649  5.787   
Amsler  19,751 103 5.736 -0.051 -2,018** 
Self-reported vision 20,198 549 5.630 -0.156 -3,514** 
OCT 20,403 754 5.830 0.044 17,256 
Visual acuity 20,444 42 5.600 -0.230 -180** 
17. Higher testing cost scenario 
OCT 19,634  5.830   
Fundus clinical evaluation 19,872 238 5.787 -0.044 -5,452** 
Amsler  19,987 353 5.736 -0.095 -3,732** 
Self-reported vision 20,372 738 5.630 -0.200 -3,688** 
Visual acuity 20,642 1008 5.600 -0.230 -4,376** 
18. Assume no further monitoring for conversion from 5 years  
OCT 19,158  5.770   
Fundus clinical evaluation 19,334 177 5.741 -0.030 -5,966** 
Amsler  19,455 297 5.705 -0.066 -659** 
Self-reported vision 19,844 686 5.621 -0.149 -2,871** 
Visual acuity 20,072 914 5.595 -0.175 -3,738** 
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